Analysts Set Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Target Price at $32.38

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $32.3750.

A number of equities research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Saturday, September 27th. Wells Fargo & Company began coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, September 3rd. They issued an “overweight” rating and a $31.00 target price for the company. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Friday, August 29th. They issued an “outperform” rating and a $40.00 price target on the stock. Truist Financial started coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Wall Street Zen cut shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 16th.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $15.56, for a total transaction of $155,600.00. Following the completion of the transaction, the insider owned 122,279 shares in the company, valued at approximately $1,902,661.24. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CTO Tia L. Bush sold 35,000 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total transaction of $840,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company’s stock, valued at approximately $2,916,072. This trade represents a 22.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 205,286 shares of company stock valued at $3,993,345 over the last quarter. Corporate insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CNTA. Adage Capital Partners GP L.L.C. lifted its stake in Centessa Pharmaceuticals by 35.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company’s stock valued at $99,999,000 after buying an additional 1,834,973 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Centessa Pharmaceuticals during the second quarter valued at about $16,052,000. Commodore Capital LP lifted its stake in Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after buying an additional 930,711 shares in the last quarter. Stempoint Capital LP lifted its stake in Centessa Pharmaceuticals by 113.3% during the second quarter. Stempoint Capital LP now owns 1,265,672 shares of the company’s stock valued at $16,631,000 after buying an additional 672,337 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in Centessa Pharmaceuticals during the first quarter valued at about $6,730,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA opened at $23.23 on Monday. The company has a market cap of $3.11 billion, a PE ratio of -12.98 and a beta of 1.57. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $24.57. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. The company has a 50-day simple moving average of $19.12 and a 200-day simple moving average of $15.31.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). On average, equities analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.